This research aims to explore how the aetiology of hepatocellular carcinoma influences the effectiveness of immunotherapy.
Investigated the effects of immune checkpoint blockade in a cohort of patients with advanced HCC
Analyzed treatment responses based on the underlying aetiology of the disease
Immune checkpoint blockade showed improved overall survival in patients with viral aetiology compared to non-viral
Significant differences in treatment response metrics were observed based on aetiological classification
Abstract
The therapeutic landscape of advanced hepatocellular carcinoma (HCC) has undergone a paradigm shift with the advent of immune checkpoint blockade (ICB).